Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosis

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses updates in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines pertaining to systemic light chain (AL) amyloidosis. Dr Kumar provides an overview of these guidelines, which emphasize matters related to diagnosis, treatment protocols for newly diagnosed and relapsing patients, and supportive care management. Dr Kumar further notes that the guidelines address potential roles for autologous stem cell transplantation (autoSCT) in amyloidosis treatment. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding for clinical trials to the institution: Abbvie, Amgen, Allogene, BMS, Carsgen, GSK, Janssen, Roche-Genentech, Takeda, Regeneron
Consulting/Advisory Board participation: (with no personal payments) Abbvie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, Beigene, and (with personal payment) Oncopeptides, Antengene